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Cancer is an umbrella term used to designate a number of diseas-
es originating from oncogenic tissues that overcome the normal 
cellular mechanisms by overexpressing self-renewal and resisting 
growth inhibiting and death promoting signals.  Cancer is rec-
ognized as a chronic, non-healing wound that strikes millions of 
lives around the globe.[1]  Based on the WHO cancer statistics, 
approximately 14.1 million newly diagnosed cases and 8.2 million 
deaths were accounted to cancer in 2012.  Further, the incidence 
of cancer is gauged to rise exponentially by 70% over upcoming 
two decades.[2]  The globalization of cancer is prominently the 
consequence of adopting cancer-enriching, modernized lifestyle 
patterns such as substance abuse (smoking and alcohol use), ces-
sation of physical activity and unhealthy dietary habits (low fruit 
and vegetable intake).[3]  The impact of cancer extends beyond 
the physical and psychological realms with significant financial 
consequences.  In addition, it enormously influences the quality of 
life (QoL); as a consequence the behavior of cancer patients and 
their family member’s decisions with regard to their treatment. 
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ABSTRACT
Metastasis is a complex and well-coordinated phenotypic transformation of cancer cells governed by aber-
rant genetic and molecular pathways.  It has been approved as the most consistent cause of cancer death. 
With emerging insight into the genomics, transcriptomics and proteomics, progress has been made and 
reasonably large number of molecular pathways of metastasis has been forwarded, but our understanding 
of precise underlying molecular mechanisms remains largely scarce.  It has been well-known for around a 
decade and more that platelets are intriguingly contributing to the cancer metastasis.  However, it is only 
recently that cancer cells can activate platelets have started to become apparent.  Surprisingly, platelets in 
response to cancer cell activation, supported by research observations, allow cancer cells to escape immune 
removal, prolong survival in vascular compartment, increased cellular adhesion and develop new cellular 
niches which eventually help to favor cancer metastasis.  Although a widely acknowledged plausible expla-
nation that cancer cells activate platelets to facilitate in their distant spread, the description of this remains 
to be confirmed.  In recent years, mucins, heavily glycosylated peptide structure, have been introduced to 
be released by several types of cancer cells.  They account for poor prognosis in wide array of malignan-
cies, because of their significant ability to induce metastatic process.  The mechanism responsible for their 
increased metastatic propensity remains uncharacterized, but recent work suggested the role of cancer 
expressed mucins in initiating platelet thrombus.  The association of cancer yield mucins, platelets and me-
tastasis therefore suggests a pressing need to explore novel molecular mechanisms and therapeutic targets 
thereafter.
[4, 5]
Metastasis entails a complex cascade of cellular and molecu-
lar events that mediate cancer cells to circulate and form second-
ary niche within distant tissue systems through ongoing bidirec-
tional interaction with the host microenvironment in a manner 
that is conducive to survival and proliferation of cancer cells.
[6]  The expression of necessary characteristics such as genetic 
and epigenetic instability, presence of cancer stem cells, immu-
noevasive self-defenses, positive interaction with foreign (host) 
microenvironments, sustained cell cycles and chemotherapeutic 
antagonism sets in motion the lethal phenotypic facet of cancer; 
metastasis.[7, 8]  Metastasis contributes to nearly 90% of cancer 
related deaths.[9]  Patients who are diagnosed with cancers that 
are metastatic at presentation tend to have poor outcomes; an im-
proved understanding of this phenomenon might provide an ad-
ditional prognostic marker.  Furthermore, the poor outcomes for 
these patients emphasize the importance of deciphering biological 
pathways contributing to metastasis as a means for developing 
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This demonstrates the crucial role of hidden molecular pathways 
harmonized by cancer derived mucins to augment the metastatic 
process.  Despite these exciting strides made over the last two 
decades, the precise mechanism of mucin platelet interaction and 
their role in cancer metastasis remains to be ascertained.
1. Conclusion
Taken together, metastasis still represents the major cause of 
cancer related mortality.  Unfortunately, the concealed molecular 
pathways guiding the primary tumors to invade distant organs 
remain to be elucidated.  Mucin, until recently, is emerging as a 
new accessory source for cancer to unfurl their metastatic terror. 
Screening of tumor with metastatic constitution is a growing con-
cern and demands aggressive measures to attenuate its negative 
prognostic impact on active cases.  On this account, experimental 
analysis will be of immense value to identify the intensity and 
precision of mucin contribution towards metastasis and its sensi-
tivity and specificity both as prognostic and diagnostic molecular 
marker.  A step towards development of accurate and reliable re-
lationship among mucin, platelets and metastasis will eventually 
yield unprecedented new insights into the future therapy.
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novel anti-metastatic therapies.  Nonetheless, the underlying 
molecular mechanisms governing these interactions are yet to be 
deciphered.
Since the discovery of Trousseau's syndrome in 1865, plate-
lets have been extensively trialed for their potential in advancing 
cancer through metastasis.[10]  Platelets, besides their established 
role in hemostasis and thrombosis, facilitate tumor invasiveness 
upon activation.  The reciprocity of cancer cells and platelets is 
critical for development of cancer metastasis.  Review studies 
supports the published evidence that thrombocytosis is directly 
proportional to the increased propensity of cancer cells to ex-
press metastatic behavior and poor prognosis and life expectancy 
among cancer patients.[11]  Studies have also documented that 
formation of ‘platelet cloak’ around cancer cells to evade immune 
cell cytotoxic lysis is at the mercy of activated platelets.  Addi-
tionally, platelet releasates carry diverse vasogenic, mitogenic and 
chemotactic factors that nurture the tumor growth and support 
metastasis.[12]  Likewise, platelets have also been implicated to 
gather leukocytes through chemical signals at the site of platelet-
cancer cell interaction, thereby mediating smooth survival of 
tumor in vascular compartment and penetration to distant organs.
[13]
Mucins, biochemically, are abundantly glycosylated proteins 
of high molecular weight with defining feature of serine and 
threonine amino acid tandem repeats.[14]  The promising physi-
ological functions of mucins such as cellular differentiation, cel-
lular adhesion, cellular signaling and immune regulation make 
them an important part of proteomics research.[15]  Conversely, 
their deviant expression in diseased states including inflammatory 
and cancerous conditions has been well reported on several occa-
sions.[16-18]  Mucins expressing human carcinomas are prone to 
increased metastasis and foreshadow poor clinical outcomes.[19] 
With the major breakthrough in molecular attributes of cancer, 
mucins and their association with platelet activation and cancer 
metastasis has assembled a lot of awareness over past few years.
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specifically the altered mucin glycoproteins are remarkable for 
their interaction with E, L and P-selectins.  Notably, selectins also 
carry the potential to recognize and bind the altered carbohydrate 
molecules expressed by cancer cells.  Certainly, such associations 
allow cancer cells to interact with blood borne cells including 
endothelial cells, leukocytes and platelets and mediate their ag-
gressive metastatic phenotype.[20-22]  Previous studies have at-
tempted to ascertain the link between the trio of mucin, platelets 
and metastasis.
Platelets can be activated by mucins in a selectin-dependent 
manner, emphasizing the importance of mucin-selectin interac-
tion, P and L-selectins in particular.  The proposed mechanism of 
platelet activation by mucin is indirect and facilitated by leuko-
cytes via interaction with L-selectin.  P-selectins and their role in 
cancer metastasis have been the subject of extensive research over 
the last few years with P-selectin expression demonstrated in acti-
vated platelets.[23, 24]  Furthermore, the ability of P-selectins to 
aggregate platelets cannot be underestimated.[25-27]  A literature 
review suggested both in vivo and in vitro interaction of platelets 
with cancer derived mucins reliant on P-selectin availability.  In 
addition, the platelet-mucin interaction without external throm-
bin utilization is supported by in vivo observation.  Experimental 
removal of mucin from cancer cell lines significantly reduces 
the strength of metastasis and studies have demonstrated that 
tumor cell-platelet aggregation as well as establishment of tu-
mor metastasis was attenuated in P-selectin-deficient mice.[28] 
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